These materials are available for nonprofit educational use. This repository is allowed by copyright disclaimer under title 17, Appendix E, section 107 of the United States Copyright Act. Under this statute, allowance is made for “fair use” for purposes such as criticism, comment, news reporting, teaching, scholarship, and research. As defined, fair use specifically applies to this repository.
- Izadi D, Layton TB, Williams L, McCann F, Cabrita M, Espirito Santo AI, et al. Identification of TNFR2 and IL-33 as therapeutic targets in localized fibrosis. Sci Adv. 2019;5(12):eaay0370. (PDF)
- Nanchahal J, Ball C, Swettenham J et al. (2017) Study protocol: A multi-centre, double blind, randomised, placebo-controlled, parallel group, phase II trial (RIDD) to determine the efficacy of intra-nodular injection of anti-TNF to controldisease progression in early Dupuytren’s disease, with an embedded dose response study. [version 2; referees: 2 approved] Wellcome Open Research 2017, :37 (PDF)
- Nanchahal J, Ball C, Swettenham J, et al. (2018) Anti-Tumour Necrosis Factor Therapy for Dupuytren’s Disease: A Randomised Dose Response Proof of Concept Phase 2a Clinical Trial. EBioMedicine journal 2. The Authors: 37. DOI: https://doi.org/10.1016/j.ebiom.2018.06.022. (PDF)
- Png ME, Dritsaki M, Gray A, Pinedo-Villanueva R, Rivero-Arias O, Nanchahal J. Economic evaluation plan of a randomised controlled trial of intra-nodular injection of anti-TNF and placebo among patients with early Dupuytren’s disease: Repurposing Anti-TNF for Treating Dupuytren’s Disease (RIDD). Wellcome Open Res. 2018;3:156. (PDF)
- Verjee LS, Verhoekx JSN, Chan JKK, et al. (2013) Unraveling the signaling pathways promoting fibrosis in Dupuytren’s disease reveals TNF as a therapeutic target. PNAS 110(10). 2013/02/23.: E928-37. (PDF)